Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or
the "Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease and overall health,
announced that the United Stated Patent and Trademark Office (USPTO)
has published notification of a Notice of Allowance for Pivotal's
U.S. Patent Application Serial Number 13/584,403 titled "Cholesterol
Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of
Cholesterol and for the Prevention or Reduction of Cardiovascular,
Cardiac and Vascular Events." This application includes claims
intended to protect VASCAZEN(R) and its formulation in conjunction
with at least one azetidinone cholesterol absorption inhibitor. This
notice constitutes allowance of the patent and impending issuance.
The issued patent would have a term that expires no earlier than in
2032.

Receipt of the Notice of Allowance in this application is further
recognition of the novel properties of VASCAZEN(R)'s formulation for
the treatment of risk factors for cardiovascular disease, reduction
of overall serum cholesterol levels, reduction in high blood
pressure, increase in the HDL:LDL ratio, and reduction of
triglycerides, particularly when utilized in combination with at
least one azetidinone cholesterol absorption inhibitor.

"We are very excited that the USPTO has allowed claims that will
protect our formulation in conjunction with a cholesterol absorption
inhibitor. We believe that the recently allowed patents combining the
key cholesterol lowering agents (Statins) and cholesterol absorption
inhibitors with our unique Omega-3 fatty acid formulation could
significantly benefit the management of cardiovascular patients going
forward," said Dr. George Jackowski, Co-Founder and Chief Scientific
Officer of Pivotal.

This application is part of an expanding patent portfolio for
Pivotal protecting its unique formulation with three (3) patent
applications now either issued or allowed with the USPTO and over
seven (7) additional applications pending in the United States.
Pivotal is also pursuing patent applications related to VASCAZEN(R)'s
formulation in multiple jurisdictions outside the United States.

About VASCAZEN(R)

VASCAZEN(R) is currently available in the U.S. as a prescription
only medical food specifically formulated for the dietary management
of an Omega-3 deficiency in cardiovascular patients. VASCAZEN(R) is a
>90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN(R) has been clinically shown in the VASCAZEN(R)-REVEAL
Trial to correct an Omega-3 deficiency within eight weeks of
treatment with positive concomitant effects on the lipid profiles,
mainly a 48% reduction of triglycerides and an increase of HDL
without negative impact on the LDL-C lipid profile. The publication
of the trial entitled "Efficacy of a unique omega-3 formulation on
the correction of nutritional deficiency and its effects on
cardiovascular disease risk factors in a randomized controlled
VASCAZEN(R)-REVEAL Trial" can be found in Molecular and Cellular
Biochemistry (MCB), http://link.springer.com/article/10.1007/s11010-0
14-2132-1/fulltext.html.

VASCAZEN(R)'s results were achieved with a dose of 3 grams of EPA
and DHA per day of a prescription grade, high purity, uniquely
formulated Omega-3.

For more information about VASCAZEN(R)please visit
http://www.vascazen.com.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a specialty pharmaceutical company with a
focus on cardiovascular disease and overall health. Pivotal
Therapeutics' lead product VASCAZEN(R) is a prescription only medical
food formulated to meet the dietary Omega-3 deficient needs of
patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels
associated with reduced risk of cardiovascular complications.
OMAZEN(R) is a pharmaceutical grade Omega-3 providing over 90% pure
Omega-3 in each capsule for the maintenance of good health. OMAZEN(R)
is a patented product available for sale and distribution in Canada.
For more information about Pivotal visit
http://www.pivotaltherapeutics.us.

Disclosure Notice

The information contained in this document is as of October 8,
2014. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as of
the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

Company Contacts: Kristine DiMatteo, Communications and Public
Relations Manager, Phone: +1-905-856-9797 ext. 231, E-Mail:
kdimatteo@pivotaltherapeutics.us; Investor & Media Contact: Stephen
Kilmer, President, Kilmer Lucas Inc., Phone: +1-647-872-4849, E-Mail:
stephen@kilmerlucas.com

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de